Synthelis is a French biotech company specialized in production, purification and characterization of membrane proteins and other difficult-to-express proteins such as ion channel, membrane transporter, GPCR, membrane enzyme and antigen.
By using Biofunds for all your search on Google, PubMed or Protocols, you can help finance Science and Research ! For Free !
Antabio is a France-based biopharma company dedicated to the discovery and development of first-in-class molecule compounds to treat severe infections caused by multi-drug resistant bacterial pathogens.
CELENYS is a biotechnology company committed to the creation, development, production and commercialization of a new generation of 3D cell culture scaffolds to bring an innovative dimension to your research.
Novaptech is a biotech company developing aptamer-based tools in the frame of technology transfer and innovation projects. Novaptech’s expertise is focused on the identification and characterization of aptamers for biotechnological development of analytical and diagnostic aptamer projects.
Click4tag is a French biotech company developing an innovative technique to rapidly detect and concentrate cultivable Gram-negative bacteria.
Click4tag – detecting pathogenic bacteria
GEG-tech is a French biotechnology company developing high performance vectorization systems based on lentiviruses. Its expertise relies on a 15-year experience R&D team. GEG-tech constantly innovates to improve lentiviral vector features, capabilities and safety.
Histalim is a service provider company in histology, immunohistochemistry (IHC), in situ hybridization (ISH), and image analysis. Its laboratory located in Montpellier was founded in 2005 while its sale offices in Berlin were opened in 2014. This positioning shows its willingness to meet the increasing demand to design, develop, and validate protocols based on standard and/or innovative techniques.
PEP Therapy is a biotech company developing targeted therapies for the treatment of severe diseases, with an initial focus on cancer.
